Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

Dumont JA, Low SC, Peters RT, Bitonti AJ.

BioDrugs. 2006;20(3):151-60. Review.

PMID:
16724863
2.

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T.

J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.

3.

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8. Epub 2004 Jun 21.

4.

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA.

Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1106-18. Epub 2006 Aug 12. Review.

PMID:
16997417
5.

Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.

Low SC, Nunes SL, Bitonti AJ, Dumont JA.

Hum Reprod. 2005 Jul;20(7):1805-13. Epub 2005 Apr 7.

PMID:
15817590
6.

Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.

Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP.

J Aerosol Med. 2005 Fall;18(3):294-303.

PMID:
16181004
7.

Fc-based cytokines : prospects for engineering superior therapeutics.

Jazayeri JA, Carroll GJ.

BioDrugs. 2008;22(1):11-26. Review.

PMID:
18215087
8.

Quantitative methods for developing Fc mutants with extended half-lives.

Kamei DT, Lao BJ, Ricci MS, Deshpande R, Xu H, Tidor B, Lauffenburger DA.

Biotechnol Bioeng. 2005 Dec 20;92(6):748-60.

PMID:
16136591
9.
10.

Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.

Bajardi-Taccioli A, Blum A, Xu C, Sosic Z, Bergelson S, Feschenko M.

Mol Immunol. 2015 Oct;67(2 Pt B):616-24. doi: 10.1016/j.molimm.2015.06.031. Epub 2015 Aug 5.

PMID:
26254986
11.

Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.

Xiao W, Chen X, Lin Zhou, Lu S, Liang Z, Wu X.

Cell Mol Immunol. 2007 Apr;4(2):147-51.

12.

Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction.

Lee CH, Woo JH, Cho KK, Kang SH, Kang SK, Choi YJ.

Biotechnol Appl Biochem. 2007 Apr;46(Pt 4):211-7.

PMID:
17067288
13.

Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.

Zhou L, Wang HY, Tong S, Okamoto CT, Shen WC, Zaro JL.

Biomaterials. 2017 Feb;117:24-31. doi: 10.1016/j.biomaterials.2016.11.051. Epub 2016 Nov 27.

PMID:
27923197
14.

Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.

Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT.

J Control Release. 2016 Feb 10;223:42-52. doi: 10.1016/j.jconrel.2015.12.033. Epub 2015 Dec 21.

PMID:
26718855
15.

Development of new models for the analysis of Fc-FcRn interactions.

Gurbaxani BM, Morrison SL.

Mol Immunol. 2006 Mar;43(9):1379-89. Epub 2005 Sep 23.

PMID:
16183124
16.

Expression and characterization of a DNase I-Fc fusion enzyme.

Dwyer MA, Huang AJ, Pan CQ, Lazarus RA.

J Biol Chem. 1999 Apr 2;274(14):9738-43.

17.

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.

Glycobiology. 2007 Jan;17(1):104-18. Epub 2006 Sep 29. Erratum in: Glycobiology. 2007 Oct;17(10):1030.

PMID:
17012310
18.

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.

Huang C.

Curr Opin Biotechnol. 2009 Dec;20(6):692-9. doi: 10.1016/j.copbio.2009.10.010. Epub 2009 Nov 4. Review.

PMID:
19889530
19.

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.

Seijsing J, Lindborg M, Höidén-Guthenberg I, Bönisch H, Guneriusson E, Frejd FY, Abrahmsén L, Ekblad C, Löfblom J, Uhlén M, Gräslund T.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17110-5. doi: 10.1073/pnas.1417717111. Epub 2014 Nov 18.

20.

Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF.

Jazayeri JA, De Weerd N, Raye W, Velkov T, Santos L, Taylor D, Carroll GJ.

J Immunol Methods. 2007 May 31;323(1):1-10. Epub 2007 Mar 28.

PMID:
17408687

Supplemental Content

Support Center